posted
Bacterial 'Gladiators' Lead To New Antibiotic Blog Name: Scientific Blogging
Tuesday, February 26, 2008
MIT biologists have provoked soil-dwelling bacteria into producing a new type of antibiotic by pitting them against another strain of bacteria in a battle for survival.
The antibiotic holds promise for treatment of Helicobacter pylori, which causes stomach ulcers in humans. Also, figuring out the still murky explanation for how the new antibiotic was produced could help scientists develop strategies for finding other new antibiotics.
A combination of luck, patience and good detective work contributed to the discovery of the new antibiotic, according to Philip Lessard, research scientist in Professor Anthony Sinskey's laboratory at MIT.
Sinskey's lab has been studying Rhodococcus, a type of soil-dwelling bacteria, for many years. While sequencing the genome of one Rhodococcus species, the researchers noticed that a large number of genes seemed to code for secondary metabolic products, which are compounds such as antibiotics, toxins and pigments.
However, Rhodococcus does not normally produce antibiotics. Many bacteria have genes for antibiotics that are only activated when the bacteria are threatened in some way, so the researchers suspected that might be true of Rhodococcus.
Kazuhiko Kurosawa, a postdoctoral associate in the Department of Biology, decided to try to provoke the bacteria into synthesizing antibiotics by placing them in stressful environments. He tried turning the temperature up and down, then altered the bacteria's growth medium, but nothing worked.
Kurosawa then decided to stress the Rhodococcus bacteria by forcing them to grow in the presence of a competing bacteria, a strain of Streptomyces. Streptomyces produces an antibiotic that normally kills other bacteria, but in one of the experimental test tubes, Rhodococcus started producing its own antibiotic, which wiped out the Streptomyces.
The researchers isolated the antibiotic, dubbed it rhodostreptomycin, and started testing it to see what else it would kill. It proved effective against many other strains of bacteria, most notably Helicobacter pylori. Rhodostreptomycin is a promising candidate to treat H. pylori because it can survive in very acidic environments such as the stomach.
The antibiotic turned out to be a type of molecule called an aminoglycoside, composed of peculiar sugars, one of which has a ring structure that has not been seen before. The ring structure could offer chemists a new target for modification, allowing them to synthesize antibiotics that are more effective and/or stable.
``Even if (rhodostreptomycin) is not the best antibiotic, it provides new structures to make chemical derivatives of,'' said Lessard. ``This may be a starting point for new antibiotics.''
One mystery still to be solved is why Rhodococcus started producing this antibiotic. One theory is that the presence of the competing strain of bacteria caused Rhodococcus to ``raise the alarm'' and turn on new genes.
The version of Rhodococcus that produces the antibiotic has a ``megaplasmid,'' or large segment of extra DNA, that it received from Streptomyces. A logical conclusion is that the plasmid carries the gene for rhodostreptomycin, but the researchers have sequenced more than half of the plasmid and found no genes that correlate to the antibiotic.
Another theory is that the plasmid itself served as the ``insult'' that provoked Rhodococcus into producing the antibiotic. Alternatively, it is possible that some kind of interaction of the two bacterial genomes produced the new antibiotic.
``Somehow the genes in the megaplasmid combined with the genes in Rhodococcus and together they produced something that neither parent could make alone,'' said Lessard.
If scientists could figure out how that happens, they could start to manipulate bacterial genomes in a more methodical fashion to design new antibiotics.
Other authors of the paper are T.G. Sambandan, research scientist in MIT's Department of Biology, MIT professors Anthony Sinskey of biology and ChoKyun Rha of the Biomaterials Science and Engineering Laboratory, and Ion Ghiviriga and Joanna Barbara of the University of Florida.
The research was funded by the Cambridge-MIT Institute and the Malaysia-MIT Biotechnology Partnership Program.
The work is reported in the February issue of the Journal of the American Chemical Society.
Posts: 294 | From nevada | Registered: Sep 2005
| IP: Logged |
treepatrol
Honored Contributor (10K+ posts)
Member # 4117
posted
wonder if these guys know about phages?
-------------------- Do unto others as you would have them do unto you. Remember Iam not a Doctor Just someone struggling like you with Tick Borne Diseases.
Fifty years after MIT researchers pioneered the use of electron microscopy to study viruses, MIT scientists have helped produce the most detailed images yet of the tiny infectious agents.
The images, which show for the first time a virus poised to inject its genetic material into a host cell, grace the cover of the Feb. 2 issue of Nature.
Scientists have known for decades that viruses infect cells by injecting their genetic material, either DNA or RNA, into host cells, but even with electron microscopy, "we could never see the details of that aspect of it," said Jonathan King, an MIT professor of biology and one of the authors of the paper.
The researchers, led by Wen Jiang and Wah Chiu of the National Center for Macromolecular Imaging at Baylor College of Medicine, focused on viruses that infect bacteria, known as bacteriophages. Their paper diagrams the structure of a virus that infects Salmonella bacteria.
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic